Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI Plus Panitumumab in KRAS/BRAF Wild-Type Metastatic Colorectal Cancer
NCT01358812Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Objective Response Rate up to 3 years. Started Mar 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01358812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358812.